ArticleThe Journal of clinical endocrinology and metabolism2025
IFN-α Neutralizing Antibodies Distinguish LADA From Early-onset Type 1 Diabetes.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Renal hypouricemia type 2 in a patient with latent autoimmune diabetes in adults: a case report and literature review.BMC nephrology · 2025Review
- IFN-α Neutralizing Antibodies Distinguish LADA From Early-onset Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
contextAutoantibodies against interferon-α (AAb-IFN-α) might be associated with the less aggressive autoimmunity in latent autoimmune diabetes in adults (LADA) compared to early-onset type 1 diabetes (T1D).
objectiveTo investigate the presence and clinical relevance of the positivity to AAb-IFN-α in people with LADA compared to T1D. RESEARCH DESIGN AND
methodsSerum levels of AAb-IFN-α isoforms were measured using a cell-based approach in 41 subjects with LADA and 90 subjects with T1D. OUTCOMES: The primary and secondary outcomes were the difference between LADA and T1D in the proportion of participants testing positive for autoantibodies (AAb) against ≥2 and against 3 interferon-α (IFN-α) isoforms, respectively. The presence and levels of AAb-IFN-α were related to clinical and biochemical features of participants with LADA.
resultsSeven (17.1%) and 5 (12.2%) participants with LADA and 3 (3.3%) and 0 participants with T1D showed positivity for AAb against ≥2 and 3 IFN-α isoforms (P = .011 and P = .0025, respectively). Fasting blood glucose and hemoglobin A1c levels were numerically lower among people with LADA testing positive for AAb against ≥2 IFN-α isoforms than among those who were either negative or positive for AAb against 1 IFN-α isoform. Among LADA-positive individuals, levels of AAb-IFN-α2 isoform were inversely correlated with glutamic acid decarboxylase antibodies levels (rho = -0.513; P = .025).
conclusionAutoimmunity against IFN-α is peculiar to autoimmune diabetes and appears to be distinctive to its slowly progressive forms. Understanding the underlying molecular mechanisms and clinical significance of this novel autoimmunity could lead to the development of new therapeutic strategies in autoimmune diseases, advancing personalized medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.